View all Medical Crossfire CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.


Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor Board

Release Date: March 20, 2017
Expiration Date: March 20, 2018
Media: Internet - based

Activity Overview

This Medical Crossfire®, titled “Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor Board,” is a multidisciplinary activity composed of experts from surgery, interventional radiology, and medical oncology, who discuss emerging data and controversial topics that are crucial to the management of patients with hepatocellular carcinoma (HCC). The goal of this activity is to provide evidence-based perspectives on the current and emerging treatment options for HCC at all stages of disease. A multidisciplinary approach to management is modeled throughout this activity.

CME Activity Table of Contents

  • Introduction
  • Module I: Overview of HCC Staging and Multidisciplinary Treatment
  • Module II: Curable HCC: What Drives Treatment Decisions?
  • Module III: Locally Advanced HCC: What Drives Treatment Decisions?
  • Module IV: Advanced Stage HCC: Assessment of Emerging Strategies and Evolving Treatment Paradigms
  • Module V: Multidisciplinary Tumor Board in Action
  • Key Takeaways
  • Posttest

  

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, "educational content/video files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, hepatologists and gastroenterologists interested in the treatment of hepatocellular carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hepatocellular carcinoma are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Discuss how co-management strategies can be optimized to improve outcomes for patients with advanced and metastatic HCC.
  2. Evaluate strategies to manage common adverse events experienced by patients with HCC.
  3. Describe recent results and ongoing clinical trials that are evaluating novel approaches to advance the management of HCC.


Faculty, Staff, and Planners' Disclosures

Chair

Ghassan K. Abou-Alfa, MD
Medical Oncologist, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Bayer, CASI Pharmaceuticals, Celgene, Chugai Pharma USA, Exelixis, Genentech, Incyte, Mabvax, Medimmune, Momenta Pharmaceuticals, OncoMed Pharmaceuticals, Roche, Vicus Therapeutics; Consultant: Aduro Biotech, Agios Pharmaceuticals, Aslan Pharmaceuticals, Astellas Pharma US, AstraZeneca, Bayer, Blueprint Medicines, Boston Scientific, BMS, Celgene, CASI, Delcath Systems, Eisai, Gilead Sciences, Halozyme Therapeutics, IntegraGen, Ipsen, Janssen, Merck, Medimmune, Merrimack, New B Innovation, NewLink Genetics, Onxeo, Roche, Sanofi-Aventis, Servier, Silenseed, Sillajen, Sirtex, Vaximm, Vicus Therapeutics, Westhaven

Faculty

Jeff Geschwind, MD
Chairman, Department of Radiology and Biomedical Imaging
Professor of Radiology and Oncology
Yale School of Medicine
New Haven, CT
Disclosure: Grant/Research Support: Boston Scientific, BTG, Guerbet, National Institutes of Health, Philips; Consultant: Bayer, Boston Scientific, BTG, Bristol-Meyers Squibb, Ethicon/J&J, Guerbet, Merck, Philips, Terumo

T. Peter Kingham, MD, FACS
Associate Attending Surgeon on the Hepatopancreatobiliary Service
Director of Global Cancer Disparity Initiatives
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: None

Stacey M. Stein, MD
Assistant Professor of Medicine (Medical Oncology)
Yale School of Medicine
New Haven, CT

Disclosure: None

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By